Cosmetic cross-reference

Luteolin

CAS 491-70-3

Luteolin (CAS 491-70-3) is a Phase 2 pharmaceutical compound with 12 bioactivity targets and 7 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Luteolin

CAS Number

491-70-3

UNII

KUX1ZNC9J2

InChIKey

IQPNAANSBPBGFQ-UHFFFAOYSA-N

ChEMBL ID

CHEMBL151

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL151 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 12 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	18854.442260869564 nM	225	-
-	Potency	17816.153731343285 nM	91	-
-	MIC	47.413888888888884 ug.mL-1	53	-
-	IC50	12.354612903225807 ug.mL-1	31	-
-	Ki	6078.83076923077 nM	26	-
-	EC50	21579.272727272728 nM	22	-
-	GI50	8.085714285714285 ug.mL-1	7	-
-	EC50	30.572000000000003 ug.mL-1	5	-
-	MIC	253456 nM	5	-
-	AC50	11511.019999999999 nM	3	-
-	Kd	4830 nM	3	-
-	GI50	4505 nM	2	-

SOURCE IUPHAR/BPS 4 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
-	-	4.960000038146973 pIC50	18710482
-	-	4.920000076293945 pIC50	18710482
TAS2R14 TAS2R14	Agonist	5.21999979019165 pEC50	24117141
TAS2R39 TAS2R39	Agonist	5.139999866485596 pEC50	24117141

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Luteolin used for in pharmaceutical contexts?

Luteolin (CAS 491-70-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Luteolin?

Luteolin has 7 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Attention deficit hyperactivity disorder, Meningitis aseptic, Surgery, Vision blurred. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Luteolin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Luteolin with EU status "permitted".

What clinical phase is Luteolin in?

Luteolin is rendered with ChEMBL max phase 2.